Semaglutide and BP, HF Risk Assessment Using Biomarkers, DAPT After Drug-Eluting Stenting in ACS
Listen now
Description
In this week’s View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP). He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation. Finally, Dr. Eagle discusses short-term dual antiplatelet therapy (DAPT) after drug-eluting stenting in patients with acute coronary syndrome (ACS).
Subscribe to Eagle’s Eye View
More Episodes
In this week’s View, Dr. Eagle looks at cardiovascular events following COVID vaccination in adults. He then explores long-term outcomes after septal reduction therapies in obstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses clinical practice guideline recommendations for...
Published 10/09/24
Published 10/09/24
In this week’s View, Dr. Eagle looks at sex-specific differences in alive hospital discharge following abdominal aortic aneurysm (AAA) repair. He then explores how diffuse interstitial fibrosis of the myocardium predicts outcomes in moderate and asymptomatic severe aortic stenosis. Finally, Dr....
Published 10/02/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
